docetaxel anhydrous has been researched along with oblimersen in 14 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (oblimersen) | Trials (oblimersen) | Recent Studies (post-2010) (oblimersen) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 195 | 40 | 27 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 13 (92.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tolcher, AW | 1 |
| Banerjee, D | 1 |
| Bouker, KB; Chen, H; Figueira, M; Frankel, SR; Hayes, DF; Ling, Y; Lippman, M; Marshall, J; Yang, D | 1 |
| Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW | 1 |
| Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
| Kaplow, R | 1 |
| Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Biroccio, A; D'Angelo, C; Leonetti, C; Scarsella, M; Semple, SC; Zupi, G | 1 |
| Tan, W | 1 |
| Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G | 1 |
| Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J | 1 |
| Calabro, F; Carpentier, P; Collette, L; Daugaard, G; Dumez, H; Gil, T; Graham, J; Lacombe, D; Sella, A; Skoneczna, I; Sternberg, CN; Van Poppel, H | 1 |
| Ataseven, B; Kaufmann, M; Kozian, D; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sohn, C; von Minckwitz, G | 1 |
2 review(s) available for docetaxel anhydrous and oblimersen
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
8 trial(s) available for docetaxel anhydrous and oblimersen
| Article | Year |
|---|---|
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Genes, bcl-2; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Thionucleotides | 2001 |
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2004 |
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Biopsy; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Thionucleotides; Time Factors | 2004 |
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Taxoids; Thionucleotides; Treatment Outcome | 2005 |
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Thionucleotides | 2008 |
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Thionucleotides | 2008 |
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2009 |
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression; Genes, bcl-2; Humans; Middle Aged; Neoadjuvant Therapy; Preoperative Period; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Thionucleotides | 2009 |
4 other study(ies) available for docetaxel anhydrous and oblimersen
| Article | Year |
|---|---|
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Thionucleotides; Tissue Extracts | 2007 |
Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; Oligodeoxyribonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Taxoids; Thionucleotides | 2007 |